Your Navigation:PCAR > Abstract
Search pcar
检索项:
检索词:
Abstract
Pharmaceutical Care and Research: 2017; 17(4):241-244,304
DOI: 10.5428/pcar20170401
Research progress of cell therapy in type 2 diabetes mellitus
1. ZHOU JingJing1(1.Department of Endocrinology,Changhai Hospital,Second Military Medical University,Shanghai 200433,China 289368165@qq.com)
2. WANG YiRan2(2.Department of Oncology,Changhai Hospital,Second Military Medical University,Shanghai 200433,China )
3. WANG QiJin1(1.Department of Endocrinology,Changhai Hospital,Second Military Medical University,Shanghai 200433,China wangqijin8668601@163.com)
ABSTRACT  The incidence of diabetes mellitus is increasing in recent years.Progressive function failure of pancreatic islet B cells and insulin resistance are the main causes of the occurrence and development of type 2 diabetes mellitus.The current treatment strategies for type 2 diabetes mellitus have limitations.As the disease progresses,long-term glycemic control and prevention of various chronic complications can not be achieved in some patients even with combined treatment of oral hypoglycemic agents and insulin intervention.Furthermore,adverse drug reactions such as hypoglycemia,weight-gain and other risks still exist,with this reason,the treatment of type 2 diatetes mellitus is not satisfactory.In recent years,cell therapy including pancreatic islet cell transplantation,stem cells transplantation,inducing conversion of pancreatic islet alpha cells to B cells and inducing conversion of hepatic cells has provided new ideas for the treatment of type 2 diabetes mellitus.The research progress in cell therapy for type 2 diabetes mellitus is reviewed in this paper,so as to provide reference for related basic and clinical researches.
Welcome to PCAR! You are the number 56 reader of this article!
Please cite this article as:
ZHOU JingJing1,WANG YiRan2,WANG QiJin1,. Research progress of cell therapy in type 2 diabetes mellitus[J]. Pharmaceutical Care and Research / yao xue fu wu yu yan jiu. 2017; 17(4): 241-244,304.
References:
1. Branch of Diabetes,Chinese Medical Association.Guidelines for the prevention and treatment of type 2 diabetes mellitus in China(2013 ed)[J].Chin J Front Med Sci(Elect version),2015,7(3):26-89.In Chinese.
2. Rickels M R.Recovery of endocrine function after islet and pancreas transplantation[J].Curr Diab Rep,2012,12(5):587-596.
3. TAN JianMing,YANG ShunLiang,CAI JinQuan,et al.Single center experience of 25 adult islet transplatation[J].Chin J Cell Stem Cell(Elect ed),2011,1(2):173-179.In Chinese with English abstract.
4. LIU YongFeng,CHENG Ying,MENG YiMan,et al.Clinical islet transplantation for type 2 diabetes mellitus:a report of 3 cases[J].Chin J Organ Transplant,2011,32 (3):156-158.In Chinese with English abstract.
5. Salama B F,Korbutt G S.Porcine islet xenografts:a clinical source of β-cell grafts[J].Curr Diab Rep,2017,17(3):14-20.
6. Zhi Z L,Kerby A,King A J,et al.Nano-scale encapsulation enhances allograft survival and function of islets transplanted in a mouse model of diabetes[J].Diabetologia,2012,55(4):1081-1090.
7. El-Badri N,Ghoneim M A.Mesenchymal stem cell therapy in diabetes mellitus:progress and challenges[J].J Nucleic Acids,2013,2013(6):194858.
8. Kroon E,Martinson L A,Kadoya K,et al.Pancreatic endoderm derived from human embryonic stem cells generates glucose-responsive insulin-secreting cells in vivo[J].Nat Biotechnol,2008,26(4):443-452.
9. Bruin J E,Saber N,Braun N,et al.Treating diet-induced diabetes and obesity with human embryonic stem cell-derived pancreatic progenitor cells and antidiabetic drugs[J].Stem Cell Reports,2015,4(4):605-620.
10. LIANG Dong,ZHANG Yang,HAN Jing,et al.Embryonic stem cell-derived pancreatic endoderm transplant with MCT1-suppressing miR-495 attenuates type 2 diabetes in mice[J].Endocr J,2015,62(10):907-920.
11. CHEN YunYa,WANG XiuJie,SHAO XinYu.A combination of human embryonic stem cell-derived pancreatic endoderm transplant with LDHA-repressing miRNA can attenuate high-fat diet induced type 2 diabetes in mice[J].J Diab Res,2015,2015:796912.
12. Shroff G.Therapeutic potential of human embryonic stem cells in type 2 diabetes mellitus[J].World J Stem Cells,2016,8(7):223-230.
13. Xin Y,Jiang X,Wang Y,et al.Insulin-producing cells differentiated from human bone marrow mesenchymal stem cells in vitro ameliorate streptozotocin-induced diabetic hyperglycemia[J].Plos One,2016,11(1):e0145838.
14. SI YiLing,ZHAO YaLi,HAO HaoJie,et al.Infusion of mesenchymal stem cells ameliorates hyperglycemia in type 2 diabetic rats:identification of a novel role in improving insulin sensitivity[J].Diabetes,2012,61(6):1616-1625.
15. Rahavi H,Hashemi S M,Soleimani M,et al.Adipose tissue-derived mesenchymal stem cells exert in vitro immunomodulatory and beta cell protective functions in streptozotocin-induced diabetic mice model[J].J Diab Res,2015,2015:878535.
16. ZHENG GuoPing,GE MengHua,QIU GuanGuan,et al.Mesenchymal stromal cells affect disease outcomes via macrophage polarization[J].Stem Cell Int,2015,2015(4):989473.
17. Bell G I,Broughton H C,Levac K D,et al.Transplanted human bone marrow progenitor subtypes stimulate endogenous islet regeneration and revascularization[J].Stem Cell Dev,2012,21(1):97-109.
18. Davey G C,Patil S B,O’Loughlin A,et al.Mesenchymal stem cell-based treatment for microvascular and secondary complications of diabetes mellitus[J].Front Endocrinol(Lausanne),2014,5:86.
19. SHEN Jing.Allogenic BM-MSC infusion ignites α to β conversion in STZ-induced diabetic rat:a new paradigm to change diabetes[D].Beijing: Medical College of PLA,2013.In Chinese with English abstract.
20. GUAN LiXue,GUAN Hui,LI HaiBo,et al.Therapeutic efficacy of umbilical cord-derived mesenchymal stem cells in patients with type 2 diabetes[J].Exp Ther Med,2015,9(5):1623-1630.
21. LIU XueBin,ZHENG Pei,WANG XiaoDong,et al.A preliminary evaluation of efficacy and safety of Wharton’s Jelly mesenchymal stem cell transplantation in patients with type 2 diabetes mellitus[J].Stem Cell Res Ther,2014,5(2):57-65.
22. Bhansali A,Asokumar P,Walia R,et al.Efficacy and safety of autologous bone marrow-derived stem cell transplantation in patients with type 2 diabetes mellitus:a randomized placebo-controlled study[J].Cell Transplant,2014,23(9):1075-1085.
23. SHI RongFeng,JIN YinPeng,CAO ChuanWu,et al.Localization of human adipose-derived stem cells and their effect in repair of diabetic foot ulcers in rats[J].Stem Cell Res Ther,2016,7(1):155-167.
24. Toso C,McCall M,Emamaullee J,et al.Liraglutide,a long-acting human glucagon-like peptide 1 analogue,improves human islet survival in culture[J].Transplant Int,2010,23(3):259-265.
25. CHEN Pin,HUANG Qin,XU XiangJin,et al.The effect of liraglutide in combination with human umbilical cord mesenchymal stem cells treatment on glucose metabolism and β cell function in type 2 diabetes mellitus[J].Chin J Intern Med,2016,(5):349-354.In Chinese with English abstract.
26. Henquin J C,Rahier J.Pancreatic alpha cell mass in European subjects with type 2 diabetes[J].Diabetologia,2011,54(7):1720-1725.
27. Thorel F,Népote V,Avril I,et al.Conversion of adult pancreatic α-cells to β-cells after extreme β-cell loss[J].Nature,2010,464(7292):1149-1154.
28. Collombat P,XU XiaoBo,Ravassard P,et al.The ectopic expression of Pax4 in the mouse pancreas converts progenitor cells into α and subsequently β cells[J].Cell,2009,138(3):449-462.
29. Lee S H,Hao E,Levine F.β-cell replication and islet neogenesis following partial pancreatectomy[J].Islets,2011,3(4):188-195.
30. Bramswig N C,Everett L J,Schug J,et al.Epigenomic plasticity enables human pancreatic α to β cell reprogramming[J].J Clin Invest,2013,123(3):1275-1284.
31. Collombat P,Mansouri A,Hecksher-Sorensen J,et al.Opposing actions of Arx and Pax4 in endocrine pancreas development[J].Genes Dev,2003,17(20):2591-2603.
32. Courtney M,Gjernes E,Druelle N,et al.The inactivation of Arx in pancreatic α-cells triggers their neogenesis and conversion into functional β-like cells[J].Plos Genet,2013,9(10):e1003934.
33. Napolitano T,Avolio F,Courtney M,et al.Pax4 acts as a key player in pancreas development and plasticity[J].Semin Cell Dev Biol,2015,44:107-114.
34. LI Jin,Casteels T,Frogne T,et al.Artemisinins target GABAA receptor signaling and impair α cell identity[J].Cell,2017,168(1):86-100.
35. Ben-Othman N,Vieira A,Courtney M,et al.Long-term GABA administration induces alpha cell-mediated beta-like cell neogenesis[J].Cell,2017,168(1-2):73-85.In French with English abstract.
36. Cerdá-Esteban N,Naumann H,Ruzittu S,et al.Stepwise reprogramming of liver cells to a pancreas progenitor state by the transcriptional regulator Tgif2[J].Nat Commun,2017,8:14127.
37. Lawandi J,TAO Chang,REN BinHai,et al.Reversal of diabetes following transplantation of an insulin-secreting human liver cell line:Melligen cells[J].Mol Ther Methods Clin Dev,2015,2:15011.
《药学服务与研究》杂志社 All Rights Reserved 网站备案号:鲁B2-20061008
·地址:上海市杨浦区长海路168号18号楼东三楼 邮政编码:200433
·联系电话(传真):86-21-65519829, 021-31162330
·电子邮件:PharmCR@vip.163.com
·技术支持:中国康网
管理员入口